MedTrace Logo

A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases

NCT07593911 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-05-18

No results posted yet for this study

Summary

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related autoimmune diseases.

Conditions

  • Systemic Lupus Erthematosus (SLE)
  • Lupus Nephritis (LN)
  • Multiple Sclerosis
  • Myasthenia Gravis (MG)
  • IgG4-Related Diseases
  • Rheumatoid Arthritis (RA)

Interventions

DRUG

MTM-H-001 Injection

Each participant receives MTM-H-001 Injection

Sponsors & Collaborators

  • MagicTime Medicine

    collaborator INDUSTRY

  • Beijing GoBroad Hospital

    lead OTHER

Principal Investigators

  • Jing Pan, Ph.D · Beijing GoBroad Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-11-30
Completion
2031-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07593911 on ClinicalTrials.gov